2019 MedChemComm Emerging Investigator Lectureship – nominations open

The 2019 MedChemComm Emerging Investigator Lectureship is now open for nominations.

Nominations will close 22 November 2018.

The recipient of the lectureship will receive a contribution of up to £1000 towards speaking at a conference in 2019.

Qualification
The lectureship is open to candidates who received their PhD in 2009 or later and who have made a significant contribution to medicinal chemistry in their early career, particularly if they have brought new ideas to drug discovery.

How you can nominate
If you would like to nominate someone please email us (medchemcomm-rsc@rsc.org) with the following details:

  • Their name
  • Their affiliation
  • At least one paragraph explaining their achievements and why you think they should be considered

Additional supporting information, for example their CV, is very helpful in making a decision but is not mandatory for making a nomination.

Self-nominations are accepted but must be supported by a letter of support from your Head of Departments or similar person at your institute.

Selection
All qualified nominations will be considered and a short-list of candidates with be selected based on the information provided at nomination. The MedChemComm Editorial Board will then vote to select the recipient and the winner will be announced in late 2018.

Previous lectureship winners include:

  • Dr. Gonçalo Bernardes (University of Cambridge, UK) – 2018
  • Dr Laura H. Heitman (Leiden University, Netherlands) – 2017
  • Dr Alessio Ciulli (University of Dundee, UK) – 2016
  • Professor Richard Payne (University of Sydney, Australia) – 2015
  • Professor Christian Heinis (École Polytechnique Fédérale de Lausanne, Switzerland) – 2013
  • Professor Patrick Gunning (University of Toronto, Canada) – 2012
Digg This
Reddit This
Stumble Now!
Share on Facebook
Bookmark this on Delicious
Share on LinkedIn
Bookmark this on Technorati
Post on Twitter
Google Buzz (aka. Google Reader)

MedChemComm welcomes Professor Jayanta Haldar to the Editorial Board

We are delighted to welcome to the team Professor Jayanta Haldar of the Jawaharlal Nehru Centre for Advanced Scientific Research (JNCASR), Bangalore, India.

Jayanta studied at Presidency College, University of Calcutta before moving to the Indian Institute of Science, Bangalore for an M.Sc. and Ph.D.. In 2004, he took up a postdoctoral position at the Massachusetts Institute of Technology, USA with Alexander Klibanov. Subsequently, Jayanta returned to India to take up an Assistant Professor position at JNCASR, his current faculty, where he was made Associate Professor in 2015.

Professor Haldar’s group specializes in the development of novel antimicrobial therapeutics, coatings and surfaces, alongside novel nano-delivery systems for drugs. To find out more about his research, take a look at the group webpage, or read a few of his many publications:

 

Selectively targeting bacteria by tuning the molecular design of membrane-active peptidomimetic amphiphiles

Chem. Commun., 2018,54, 4943-4946, DOI: 10.1039/C8CC01926F

 

L-Lysine based lipidated biphenyls as agents with anti-biofilm and anti-inflammatory properties that also inhibit intracellular bacteria

Chem. Commun., 2017,53, 8427-8430, DOI: 10.1039/C7CC04206J

 

A review on cell wall synthesis inhibitors with an emphasis on glycopeptide antibiotics

Med. Chem. Commun., 2017,8, 516-533, DOI: 10.1039/C6MD00585C

 

Aryl-alkyl-lysines: small molecular membrane-active antiplasmodial agents

Med. Chem. Commun., 2017,8, 434-439, DOI: 10.1039/C6MD00589F

Digg This
Reddit This
Stumble Now!
Share on Facebook
Bookmark this on Delicious
Share on LinkedIn
Bookmark this on Technorati
Post on Twitter
Google Buzz (aka. Google Reader)

Introducing new MedChemComm Editor-in-Chief, Professor Gerhard Ecker

MedChemComm Editor-in-Chief Gerhard Ecker

MedChemComm is very excited to welcome to the team our new Editor-in-Chief, Professor Gerhard Ecker. Prof. Ecker is the current head of the Pharmacoinformatics Research Group in the Department of Medicinal Chemistry at the University of Vienna. His research interests include ligand- and structure-based drug design, focusing on transmembrane transport proteins and the prediction of on- and off-kinetics, as well as semantic data integration.

He completed his PhD at the University of Vienna under the supervision of Professor Fleischhacker and Professor Noe before taking a post-doctoral position with Professor Seydel’s group in Borstel, Germany.

Gerhard has previously held positions as President of the European Federation for Medicinal Chemistry and vice-president of the Austrian Pharmaceutical Society.

 

He has published over 100 full papers, including:

Probing the stereoselectivity of P-glycoprotein-synthesis, biological activity and ligand docking studies of a set of enantiopure benzopyrano[3,4-b][1,4]oxazines
Chem. Commun., 2011, 47, 2586-2588

Open PHACTS computational protocols for in silico target validation of cellular phenotypic screens: knowing the knowns
Med. Chem. Commun., 2016, 7, 1237-1244

From linked open data to molecular interaction: studying selectivity trends for ligands of the human serotonin and dopamine transporter
Med. Chem. Commun., 2016, 7, 1819-1831

 

For more information, visit his lab group website.

Digg This
Reddit This
Stumble Now!
Share on Facebook
Bookmark this on Delicious
Share on LinkedIn
Bookmark this on Technorati
Post on Twitter
Google Buzz (aka. Google Reader)

Outstanding Reviewers for MedChemComm in 2017

Outstanding Reviewers for MedChemComm in 2017

We would like to highlight the Outstanding Reviewers for MedChemComm in 2017, as selected by the editorial team, for their significant contribution to the journal. The reviewers have been chosen based on the number, timeliness and quality of the reports completed over the last 12 months.

We would like to say a big thank you to those individuals listed here as well as to all of the reviewers that have supported the journal. Each Outstanding Reviewer will receive a certificate to give recognition for their significant contribution.

Dr Andreas Brunschweiger, TU Dortmund, Germany, ORCID: 0000-0002-4401-1495 
Dr David Colby, University of Mississippi, USA, ORCID: 0000-0002-5434-1690
Professor Paul Furtmüller, BOKU-University of Natural Resources and Life Sciences, Austria, ORCID: 0000-0002-1199-2469
Dr Keith Green, University of Kentucky, USA
Dr Ke Jiang, Stanford University, USA
Dr Mukulesh Mondal, Oakland University, USA
Dr Concepcion Sanchez-Martinez, Lilly, Spain, ORCID: 0000-0003-0221-497X
Professor Mike Waring, Newcastle University, UK, ORCID: 0000-0002-9110-8783
Dr Zhiqiang Yu, Southern Medical University, China
Dr Ye Zhang, Guangxi Normal University, China, ORCID: 0000-0002-6903-5602

We would also like to thank the MedChemComm board and the wider community for their continued support of the journal, as authors, reviewers and readers.

If you would like to become a reviewer for our journal you can find more details in our author and reviewer resource centre

Digg This
Reddit This
Stumble Now!
Share on Facebook
Bookmark this on Delicious
Share on LinkedIn
Bookmark this on Technorati
Post on Twitter
Google Buzz (aka. Google Reader)

Dr. Gonçalo Bernardes wins the 2018 Emerging Investigator Lectureship

We are delighted to announce that Dr. Gonçalo Bernardes has been selected to receive the 2018 MedChemComm Emerging Investigator Lectureship

The lectureship was open to any candidate who received their PhD in 2008 or later and have made a significant contribution to medicinal chemistry in their early career. The Editorial Board feel that his substantial contributions to the chemistry of protein conjugates, and his impact on the field of antibody conjugates make him an excellent choice for this year’s lectureship.

On being informed of his selection Dr. Bernardes said:

I am honoured to receive this distinction from an organisation I admire so much and so incredibly proud of the work of my entire research group at Cambridge and iMM Lisbon.”

Dr. Bernardes will give his lecture later this year at a conference to be confirmed.

About Dr. Gonçalo Bernardes

Dr. Gonçalo Bernardes is a Group Leader at the Department of Chemistry, University of Cambridge, U.K.. He is also the Director of the Chemical Biology and Pharmaceutical Biotechnology Unit at the Instituto de Medicina Molecular, Portugal. After completing his D.Phil. degree in 2008 at the University of Oxford, U.K., he undertook postdoctoral work at the Max-Planck Institute of Colloids and Interfaces, Germany, and the ETH Zürich, Switzerland, and worked as a Group Leader at Alfama Lda in Portugal. He started his independent research career in 2013, and his research group tackles a range of biological problems of fundamental importance to understand and fight human disease primarily through the use of chemistry principles. He is a Royal Society University Research Fellow and the awardee of a Starting Grant from the European Research Council (TagIt).

Visit Gonçalo’s homepage to find out more about his ongoing research.

Digg This
Reddit This
Stumble Now!
Share on Facebook
Bookmark this on Delicious
Share on LinkedIn
Bookmark this on Technorati
Post on Twitter
Google Buzz (aka. Google Reader)

What are your colleagues reading in MedChemComm?

The articles below are some of the most read MedChemComm articles in April, May and June 2017.

Review Articles:

Multivalent glycoconjugates as vaccines and potential drug candidates
Sumati Bhatia, Mathias Dimde and Rainer Haag
DOI: 10.1039/C4MD00143E

Surface plasmon resonance for the characterization of bacterial polysaccharide antigens: a review
Barbara Brogioni and Francesco Berti
DOI: 10.1039/C4MD00088A

Recent advances in the rational design and optimization of antibacterial agents
Jesse A. Jones, Kristopher G. Virga, Giuseppe Gumina and Kirk E. Hevener
DOI: 10.1039/C6MD00232C

Polypharmacology modelling using proteochemometrics (PCM): recent methodological developments, applications to target families, and future prospects
Isidro Cortés-Ciriano, Qurrat Ul Ain, Vigneshwari Subramanian, Eelke B. Lenselink, Oscar Méndez-Lucio, Adriaan P. IJzerman, Gerd Wohlfahrt, Peteris Prusis, Thérèse E. Malliavin, Gerard J. P. van Westen and Andreas Bender
DOI: 10.1039/C4MD00216D

Protein–ligand (un)binding kinetics as a new paradigm for drug discovery at the crossroad between experiments and modelling
M. Bernetti, A. Cavalli and L. Mollica
DOI: 10.1039/C6MD00581K

Structural biology and chemistry of protein arginine methyltransferases
Matthieu Schapira and Renato Ferreira de Freitas
DOI: 10.1039/C4MD00269E

Small molecule-mediated protein knockdown as a new approach to drug discovery
Christopher P. Tinworth, Hannah Lithgow and Ian Churcher
DOI: 10.1039/C6MD00347H

Chemical probes and inhibitors of bromodomains outside the BET family
Moses Moustakim, Peter G. K. Clark, Duncan A. Hay, Darren J. Dixon and Paul E. Brennan
DOI: 10.1039/C6MD00373G

Amphiphilic designer nano-carriers for controlled release: from drug delivery to diagnostics
Malinda Salim, Hiroyuki Minamikawa, Akihiko Sugimura and Rauzah Hashim
DOI: 10.1039/C4MD00085D

2-[18F]Fluoroethyl tosylate – a versatile tool for building 18F-based radiotracers for positron emission tomography
Torsten Kniess, Markus Laube, Peter Brust and Jörg Steinbach
DOI: 10.1039/C5MD00303B

Structural features of many circular and leaderless bacteriocins are similar to those in saposins and saposin-like peptides
K. M. Towle and J. C. Vederas
DOI: 10.1039/C6MD00607H

Bacterial lipid membranes as promising targets to fight antimicrobial resistance, molecular foundations and illustration through the renewal of aminoglycoside antibiotics and emergence of amphiphilic aminoglycosides
Marie-Paule Mingeot-Leclercq and Jean-Luc Décout
DOI: 10.1039/C5MD00503E

Research Articles:

Towards understanding cell penetration by stapled peptides
Qian Chu, Raymond E. Moellering, Gerard J. Hilinski, Young-Woo Kim, Tom N. Grossmann, Johannes T.-H. Yeh and Gregory L. Verdine
DOI: 10.1039/C4MD00131A

Design and synthesis of DNA-encoded libraries based on a benzodiazepine and a pyrazolopyrimidine scaffold
M. Klika Škopić, O. Bugain, K. Jung, S. Onstein, S. Brandherm, T. Kalliokoski and A. Brunschweiger
DOI: 10.1039/C6MD00243A

Methods of protein surface PEGylation under structure preservation for the emulsion-based formation of stable nanoparticles
Lydia Radi, Matthias Fach, Mirko Montigny, Elena Berger-Nicoletti, Wolfgang Tremel and Peter R. Wich
DOI: 10.1039/C5MD00475F

Identification of imidazo[1,2-b]pyridazine TYK2 pseudokinase ligands as potent and selective allosteric inhibitors of TYK2 signalling
R. Moslin, D. Gardner, J. Santella, Y. Zhang, J. V. Duncia, C. Liu, J. Lin, J. S. Tokarski, J. Strnad, D. Pedicord, J. Chen, Y. Blat, A. Zupa-Fernandez, L. Cheng, H. Sun, C. Chaudhry, C. Huang, C. D’Arienzo, J. S. Sack, J. K. Muckelbauer, C. Chang, J. Tredup, D. Xie, N. Aranibar, J. R. Burke, P. H. Carter and D. S. Weinstein
DOI: 10.1039/C6MD00560H

Exploring the links between peptoid antibacterial activity and toxicity
H. L. Bolt, G. A. Eggimann, C. A. B. Jahoda, R. N. Zuckermann, G. J. Sharples and S. L. Cobb
DOI: 10.1039/C6MD00648E

Nonomuraea sp. ATCC 55076 harbours the largest actinomycete chromosome to date and the kistamicin biosynthetic gene cluster
Behnam Nazari, Clarissa C. Forneris, Marcus I. Gibson, Kyuho Moon, Kelsey R. Schramma and Mohammad R. Seyedsayamdost
DOI: 10.1039/C6MD00637J

Structure-based virtual screening for fragment-like ligands of the G protein-coupled histamine H4 receptor
Enade P. Istyastono, Albert J. Kooistra, Henry F. Vischer, Martien Kuijer, Luc Roumen, Saskia Nijmeijer, Rogier A. Smits, Iwan J. P. de Esch, Rob Leurs and Chris de Graaf
DOI: 10.1039/C5MD00022J

Human lysosomal acid lipase inhibitor lalistat impairs Mycobacterium tuberculosis growth by targeting bacterial hydrolases
J. Lehmann, J. Vomacka, K. Esser, M. Nodwell, K. Kolbe, P. Rämer, U. Protzer, N. Reiling and S. A. Sieber
DOI: 10.1039/C6MD00231E

Design and synthesis of potent and selective inhibitors of BRD7 and BRD9 bromodomains
Duncan A. Hay, Catherine M. Rogers, Oleg Fedorov, Cynthia Tallant, Sarah Martin, Octovia P. Monteiro, Susanne Müller, Stefan Knapp, Christopher J. Schofield and Paul E. Brennan
DOI: 10.1039/C5MD00152H

A fundamental view of enthalpy–entropy compensation
Ulf Ryde
DOI: 10.1039/C4MD00057A

Optimisation of a triazolopyridine based histone demethylase inhibitor yields a potent and selective KDM2A (FBXL11) inhibitor
Katherine S. England, Anthony Tumber, Tobias Krojer, Giuseppe Scozzafava, Stanley S. Ng, Michelle Daniel, Aleksandra Szykowska, KaHing Che, Frank von Delft, Nicola A. Burgess-Brown, Akane Kawamura, Christopher J. Schofield and Paul E. Brennan
DOI: 10.1039/C4MD00291A

From linked open data to molecular interaction: studying selectivity trends for ligands of the human serotonin and dopamine transporter
Barbara Zdrazil, Eva Hellsberg, Michael Viereck and Gerhard F. Ecker
DOI: 10.1039/C6MD00207B

Keep up-to-date with the latest issues of MedChemComm with our E-alerts

Digg This
Reddit This
Stumble Now!
Share on Facebook
Bookmark this on Delicious
Share on LinkedIn
Bookmark this on Technorati
Post on Twitter
Google Buzz (aka. Google Reader)

Nominations for the 2018 MedChemComm Emerging Investigator Lectureship – Now Open

The 2018 MedChemComm Emerging Investigator Lectureship is now open for nominations.

Nominations will close 28 November 2017.

The recipient of the lectureship will receive a contribution of up to £1000 towards speaking at a conference in 2018.

Qualification The lectureship is open to candidates who received their PhD in 2008 or later and who have made a significant contribution to medicinal chemistry in their early career, particularly if they have brought new ideas to drug discovery.

How you can nominate If you would like to nominate someone please email us (medchemcomm-rsc@rsc.org) with the following details:

  • Their name
  • Their affiliation
  • At least one paragraph explaining their achievements and why you think they should be considered

Additional supporting information, for example their CV, is very helpful in making a decision but is not mandatory for making a nomination.

Self-nominations are accepted but must be supported by a letter of support from your Head of Departments or similar person at your institute.

Selection All qualified nominations will be considered and a short-list of candidates with be selected based on the information provided at nomination. The MedChemComm Editorial Board will then vote to select the recipient and the winner will be announced in late 2017.

Previous lectureship winners include:

  • Dr Laura H. Heitman (Leiden University, Netherlands) – 2017 Winner
  • Dr Alessio Ciulli (University of Dundee, UK) – 2016 Winner
  • Professor Richard Payne (University of Sydney, Australia) – 2015 Winner
  • Professor Christian Heinis (École Polytechnique Fédérale de Lausanne, Switzerland) – 2013 Winner
  • Professor Patrick Gunning (University of Toronto, Canada) – 2012 Winner
Digg This
Reddit This
Stumble Now!
Share on Facebook
Bookmark this on Delicious
Share on LinkedIn
Bookmark this on Technorati
Post on Twitter
Google Buzz (aka. Google Reader)

Outstanding Reviewers for MedChemComm in 2016

Following the success of Peer Review Week in September 2016 (dedicated to reviewer recognition) during which we published a list of our top reviewers, we will continue to recognise the contribution that our reviewers make to the journal by announcing our Outstanding Reviewers each year.

Outstanding Reviewers for MedChemComm in 2016, as selected by the editorial team, have been chosen based on the number, timeliness and quality of the reports completed over the last 12 months.

A big thank you to those individuals listed here as well as to all of the reviewers that have supported the journal. Each Outstanding Reviewer will receive a certificate to give recognition for their significant contribution.

Dr Simone Carradori, University of Chieti-Pescara

Professor David A. Colby, University of Mississippi

Dr Abasaheb Dhawane, Georgia State University

Dr Zhang Jiancun, Chinese Academy of Sciences

Professor Zhengqui Li, Jinan University

Dr Xiaoyun Lu, Chinese Academy of Sciences

Dr Enas Malik, University of Bonn

Dr Sandeep Sundriyal, Imperial College London

Dr Kazuya Tatani, Kissei Pharmaceuticals Co. Ltd.

Dr Xu Yong, Chinese Academy of Sciences

We would also like to thank the MedChemComm boards and the medicinal chemistry community for their continued support of the journal, as authors, reviewers and readers.

If you would like to become a reviewer for our journal, just email us with details of your research interests and an up-to-date CV or résumé.  You can find more details in our author and reviewer resource centre

 

Digg This
Reddit This
Stumble Now!
Share on Facebook
Bookmark this on Delicious
Share on LinkedIn
Bookmark this on Technorati
Post on Twitter
Google Buzz (aka. Google Reader)

2017 MedChemComm Emerging Investigator Lectureship Winner

Congratulations to Dr Laura H. Heitman from Leiden University, Netherlands, the recipient of the 2017 MedChemComm Emerging Investigator Lectureship!

The Lectureship was open to any candidate who received their PhD in 2007 or later and have made a significant contribution to medicinal chemistry in their early career. The MedChemComm Editorial Board then voted on a short-list of nominations.

Many Congratulations to Dr. Heitman for winning the lectureship. Due to current circumstances, Dr. Heitman will be looking to do her lectureship in 2018.

 

About Laura

Laura H. Heitman, PhD. is a tenured associate professor of Molecular Pharmacology at the Division of Medicinal Chemistry at the Leiden Academic Centre for Drug Research (LACDR, Leiden University), after being appointed as ‘tenure track’ assistant professor in January 2009. She obtained her PhD degree in April 2009 for her thesis on “Allosteric modulation of ‘reproductive’ GPCRs” in collaboration with Organon/MSD (Oss, The Netherlands). Her research interests are mainly focused on understanding and improving drug-receptor interactions, and more specifically, target binding kinetics and allosteric modulation of GPCRs. In the last couple of years, she has obtained several competitive research grants (e.g. IMI-Kinetics for Drug Discovery/K4DD), all allowing her to study these novel, clinically relevant and highly translational concepts for drug action. Her research activities have currently led to an authorship on over 50 papers in this field, including one in Science (2012) and one in Nature (2016).

Digg This
Reddit This
Stumble Now!
Share on Facebook
Bookmark this on Delicious
Share on LinkedIn
Bookmark this on Technorati
Post on Twitter
Google Buzz (aka. Google Reader)

Poster prize winner at the 8th BrazMedChem Symposium

Daniel receiving his prize from Prof. Koen Augustyns of MedChemComm‘s Editorial Board

Congratulations to the poster prize winner at the BrazMedChem Symposium 2016.

We were pleased to present a prize to Daniel A. Rodrigues (LASSBio-UFRJ-Federal University of Rio de Janeiro; Supervisor: Carlos M. Fraga) for his poster:

“Antiproliferative activity and chemical stability of novel N-acylhydrazones dual inhibitors of HDAC6/8″

The symposium took place in Armação dos Búzios, Rio de Janeiro on 27-30 November 2016. A short video summary of the event can be seen at https://youtu.be/lRi_nMNX5oM

The main goal of BrazMedChem2016 was to provide a scientific atmosphere to stimulate the cooperation between scientists from Brazil and abroad. To facilitate the exchange of experiences and information among researchers is essential in order to meet the challenges of medicinal chemistry of the twenty-first century.

 

Digg This
Reddit This
Stumble Now!
Share on Facebook
Bookmark this on Delicious
Share on LinkedIn
Bookmark this on Technorati
Post on Twitter
Google Buzz (aka. Google Reader)